Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy

Go Kaneko, Suguru Shirotake, Koshiro Nishimoto, Yasumasa Miyazaki, Keiichi Ito, Yujiro Ito, Masayuki Hagiwara, Kent Kanao, Ken Nakagawa, Tetsuo Momma, Tomohiko Asano, Nobuyuki Tanaka, Ryuichi Mizuno, Mototsugu Oya, Masafumi Oyama

Research output: Contribution to journalArticle

Abstract

Background: International Metastatic Renal Cell Carcinoma Database Consortium model predicts the outcomes of metastatic renal cell carcinoma stratified into favorable, intermediate, and poor risk groups (FG, IG, and PG, respectively), with approximately 50% of patients being classified as IG. We aimed to generate better risk model based on the sub-classification of IG. Methods: We analyzed records of 213 consecutive patients receiving molecular targeted therapy. Age, gender, histology, type of initial molecular targeted therapy, serum laboratory data, previous nephrectomy and immunotherapy, and metastatic sites were used for IG sub-stratification. Modified and original models were compared using a concordance correlation coefficient analysis. Results: Median follow-up was 17.8 months. Serum albumin, serum C-reactive protein, and bone metastases were independent predictors of overall survival (OS) in IG. IG was sub-classified into low-, middle-, and high-risk IG according to the number of predictors. The following modified model was developed: modified FG (FG & low-risk IG), modified IG (middle-risk IG), and modified PG (PG & high-risk IG). Concordance indices for original and modified models were 0.68 and 0.73, respectively (P < 0.001). OS was significantly longer in modified PG treated with mammalian target of rapamycin inhibitors as second-line therapy than with tyrosine kinase inhibitors, whereas this was not observed in the original model. Conclusions: We successfully developed modified IMDC model using a two-step process: the original IMDC plus an IG sub-stratification, and demonstrated that it predicts outcomes more accurately than original model.

Original languageEnglish
Pages (from-to)780-785
Number of pages6
JournalJapanese journal of clinical oncology
Volume49
Issue number8
DOIs
Publication statusPublished - 2019 Aug 1

Fingerprint

Renal Cell Carcinoma
Molecular Targeted Therapy
Therapeutics
Survival
Sirolimus
Nephrectomy
Serum Albumin
C-Reactive Protein
Protein-Tyrosine Kinases
Immunotherapy
Blood Proteins
Histology
Databases
Neoplasm Metastasis
Bone and Bones
Serum

Keywords

  • Intermediate risk
  • International Metastatic Renal Cell Carcinoma Database Consortium model
  • Metastatic renal cell carcinoma
  • Molecular target therapy
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy. / Kaneko, Go; Shirotake, Suguru; Nishimoto, Koshiro; Miyazaki, Yasumasa; Ito, Keiichi; Ito, Yujiro; Hagiwara, Masayuki; Kanao, Kent; Nakagawa, Ken; Momma, Tetsuo; Asano, Tomohiko; Tanaka, Nobuyuki; Mizuno, Ryuichi; Oya, Mototsugu; Oyama, Masafumi.

In: Japanese journal of clinical oncology, Vol. 49, No. 8, 01.08.2019, p. 780-785.

Research output: Contribution to journalArticle

Kaneko, G, Shirotake, S, Nishimoto, K, Miyazaki, Y, Ito, K, Ito, Y, Hagiwara, M, Kanao, K, Nakagawa, K, Momma, T, Asano, T, Tanaka, N, Mizuno, R, Oya, M & Oyama, M 2019, 'Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy', Japanese journal of clinical oncology, vol. 49, no. 8, pp. 780-785. https://doi.org/10.1093/jjco/hyz067
Kaneko, Go ; Shirotake, Suguru ; Nishimoto, Koshiro ; Miyazaki, Yasumasa ; Ito, Keiichi ; Ito, Yujiro ; Hagiwara, Masayuki ; Kanao, Kent ; Nakagawa, Ken ; Momma, Tetsuo ; Asano, Tomohiko ; Tanaka, Nobuyuki ; Mizuno, Ryuichi ; Oya, Mototsugu ; Oyama, Masafumi. / Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy. In: Japanese journal of clinical oncology. 2019 ; Vol. 49, No. 8. pp. 780-785.
@article{aca43daff9a643eda6447f7e65bef3ce,
title = "Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy",
abstract = "Background: International Metastatic Renal Cell Carcinoma Database Consortium model predicts the outcomes of metastatic renal cell carcinoma stratified into favorable, intermediate, and poor risk groups (FG, IG, and PG, respectively), with approximately 50{\%} of patients being classified as IG. We aimed to generate better risk model based on the sub-classification of IG. Methods: We analyzed records of 213 consecutive patients receiving molecular targeted therapy. Age, gender, histology, type of initial molecular targeted therapy, serum laboratory data, previous nephrectomy and immunotherapy, and metastatic sites were used for IG sub-stratification. Modified and original models were compared using a concordance correlation coefficient analysis. Results: Median follow-up was 17.8 months. Serum albumin, serum C-reactive protein, and bone metastases were independent predictors of overall survival (OS) in IG. IG was sub-classified into low-, middle-, and high-risk IG according to the number of predictors. The following modified model was developed: modified FG (FG & low-risk IG), modified IG (middle-risk IG), and modified PG (PG & high-risk IG). Concordance indices for original and modified models were 0.68 and 0.73, respectively (P < 0.001). OS was significantly longer in modified PG treated with mammalian target of rapamycin inhibitors as second-line therapy than with tyrosine kinase inhibitors, whereas this was not observed in the original model. Conclusions: We successfully developed modified IMDC model using a two-step process: the original IMDC plus an IG sub-stratification, and demonstrated that it predicts outcomes more accurately than original model.",
keywords = "Intermediate risk, International Metastatic Renal Cell Carcinoma Database Consortium model, Metastatic renal cell carcinoma, Molecular target therapy, Renal cell carcinoma",
author = "Go Kaneko and Suguru Shirotake and Koshiro Nishimoto and Yasumasa Miyazaki and Keiichi Ito and Yujiro Ito and Masayuki Hagiwara and Kent Kanao and Ken Nakagawa and Tetsuo Momma and Tomohiko Asano and Nobuyuki Tanaka and Ryuichi Mizuno and Mototsugu Oya and Masafumi Oyama",
year = "2019",
month = "8",
day = "1",
doi = "10.1093/jjco/hyz067",
language = "English",
volume = "49",
pages = "780--785",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy

AU - Kaneko, Go

AU - Shirotake, Suguru

AU - Nishimoto, Koshiro

AU - Miyazaki, Yasumasa

AU - Ito, Keiichi

AU - Ito, Yujiro

AU - Hagiwara, Masayuki

AU - Kanao, Kent

AU - Nakagawa, Ken

AU - Momma, Tetsuo

AU - Asano, Tomohiko

AU - Tanaka, Nobuyuki

AU - Mizuno, Ryuichi

AU - Oya, Mototsugu

AU - Oyama, Masafumi

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: International Metastatic Renal Cell Carcinoma Database Consortium model predicts the outcomes of metastatic renal cell carcinoma stratified into favorable, intermediate, and poor risk groups (FG, IG, and PG, respectively), with approximately 50% of patients being classified as IG. We aimed to generate better risk model based on the sub-classification of IG. Methods: We analyzed records of 213 consecutive patients receiving molecular targeted therapy. Age, gender, histology, type of initial molecular targeted therapy, serum laboratory data, previous nephrectomy and immunotherapy, and metastatic sites were used for IG sub-stratification. Modified and original models were compared using a concordance correlation coefficient analysis. Results: Median follow-up was 17.8 months. Serum albumin, serum C-reactive protein, and bone metastases were independent predictors of overall survival (OS) in IG. IG was sub-classified into low-, middle-, and high-risk IG according to the number of predictors. The following modified model was developed: modified FG (FG & low-risk IG), modified IG (middle-risk IG), and modified PG (PG & high-risk IG). Concordance indices for original and modified models were 0.68 and 0.73, respectively (P < 0.001). OS was significantly longer in modified PG treated with mammalian target of rapamycin inhibitors as second-line therapy than with tyrosine kinase inhibitors, whereas this was not observed in the original model. Conclusions: We successfully developed modified IMDC model using a two-step process: the original IMDC plus an IG sub-stratification, and demonstrated that it predicts outcomes more accurately than original model.

AB - Background: International Metastatic Renal Cell Carcinoma Database Consortium model predicts the outcomes of metastatic renal cell carcinoma stratified into favorable, intermediate, and poor risk groups (FG, IG, and PG, respectively), with approximately 50% of patients being classified as IG. We aimed to generate better risk model based on the sub-classification of IG. Methods: We analyzed records of 213 consecutive patients receiving molecular targeted therapy. Age, gender, histology, type of initial molecular targeted therapy, serum laboratory data, previous nephrectomy and immunotherapy, and metastatic sites were used for IG sub-stratification. Modified and original models were compared using a concordance correlation coefficient analysis. Results: Median follow-up was 17.8 months. Serum albumin, serum C-reactive protein, and bone metastases were independent predictors of overall survival (OS) in IG. IG was sub-classified into low-, middle-, and high-risk IG according to the number of predictors. The following modified model was developed: modified FG (FG & low-risk IG), modified IG (middle-risk IG), and modified PG (PG & high-risk IG). Concordance indices for original and modified models were 0.68 and 0.73, respectively (P < 0.001). OS was significantly longer in modified PG treated with mammalian target of rapamycin inhibitors as second-line therapy than with tyrosine kinase inhibitors, whereas this was not observed in the original model. Conclusions: We successfully developed modified IMDC model using a two-step process: the original IMDC plus an IG sub-stratification, and demonstrated that it predicts outcomes more accurately than original model.

KW - Intermediate risk

KW - International Metastatic Renal Cell Carcinoma Database Consortium model

KW - Metastatic renal cell carcinoma

KW - Molecular target therapy

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85074378644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074378644&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyz067

DO - 10.1093/jjco/hyz067

M3 - Article

C2 - 31063191

AN - SCOPUS:85074378644

VL - 49

SP - 780

EP - 785

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 8

ER -